Terms ending in 2041
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,365,729 | Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis In force · High confidence | AbbVie Deutschland GmbH & Co. KG | In force | High confidence | |
| US 12,497,452 | Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis In force · High confidence | AbbVie Deutschland GmbH & Co. KG | In force | High confidence | |
| US D1,133,906 | Container Cap In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,639,390 | ANTI-ALPHA-4-BETA-7 Antibodies In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,897,672 | Sleeve Containers for Packaging Medicinal Products In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US D1,154,095 | Carrying Pack for Medical Device In force · High confidence | AbbVie Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.